Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAmidst rising costs across all areas of our business, and aggressive attempts to implement cost savings without sacrificing quality, we announce the need to implement a cost increase starting July 1, 2022. If you have questions, please contact your sales representative.
PHCCC is a group I metabotropic glutamate receptor antagonist (IC50 ~ 3 μM); 67 times more potent than (S)-4-carboxyphenylglycine (Cat. No. 0323). Also a positive allosteric modulator for mGlu4a; potentiates L-AP4-mediated inhibition of striatopallidal synaptic transmission in vitro. Displays antiParkinsonian effects in rats in vivo.
Sold for research purposes under license from Suntory Ltd.
PHCCC is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 294.31 |
Formula | C17H14N2O3 |
Storage | Store at RT |
Purity | ≥98% (HPLC) |
CAS Number | 179068-02-1 |
PubChem ID | 5866327 |
InChI Key | FPXPIEZPAXSELW-CYVLTUHYSA-N |
Smiles | O=C(NC4=CC=CC=C4)C3(C2C3)OC1=CC=CC=C1/C2=N/O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 29.43 | 100 |
The following data is based on the product molecular weight 294.31. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.4 mL | 16.99 mL | 33.98 mL |
5 mM | 0.68 mL | 3.4 mL | 6.8 mL |
10 mM | 0.34 mL | 1.7 mL | 3.4 mL |
50 mM | 0.07 mL | 0.34 mL | 0.68 mL |
References are publications that support the biological activity of the product.
Mao and Wang (2001) Selective activation of group I metabotropic glutamate receptors upregulates preprodynorphin, substance P and preproenkephalin mRNA expression in rat dorsal striatum. Synapse 39 82 PMID: 11071713
Marino et al (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc.Natl.Acad.Sci.USA 100 13668 PMID: 14593202
Annoura et al (1996) A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorg.Med.Chem.Lett. 6 763
Flor et al (2002) Positive allosteric modulators of metabotropic glutamate receptor subtype 4: pharmacological and molecular characterization. Neuropharmacology 43 286 Abstr.No. 47
If you know of a relevant reference for PHCCC, please let us know.
View all Glutamate (Metabotropic) Group I Receptor Antagonists
Keywords: PHCCC, PHCCC supplier, Potent, group, I, mGlur, antagonists, Group, Receptors, mGlu1, mGlu5, Glutamate, Metabotropic, mGlu4, (Metabotropic), 1027, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for PHCCC include:
Broadstock et al (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165 1034 PMID: 21627638
Volpi et al (2016) Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells. Neuropharmacology 102 59 PMID: 26522434
Spampinato et al (2015) Glial metabotropic glutamate receptor-4 increases maturation and survival of oligodendrocytes. Biol Psychiatry 8 462 PMID: 25642169
Niswender et al (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 74 1345 PMID: 18664603
Foong (2009) mGluR(1) Receptors Contribute to Non-Purinergic Slow Excitatory Transmission to Submucosal VIP Neurons of Guinea-Pig Ileum. Front Neurosci 3 46 PMID: 20582273
Jones et al (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 ( J Med Chem 54 7639 PMID: 21966889
Hemstapat et al (2006) A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol Pharmacol 70 616 PMID: 16645124
Collard et al (2002) Neutrophil-derived glutamate regulates vascular endothelial barrier function. J Biol Chem 277 14801 PMID: 11847215
Do you know of a great paper that uses PHCCC from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review PHCCC and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.